Generated September 5, 2026.
Overview
ARKG and HLTH are both actively managed healthcare-focused ETFs launched by different issuers, but they target distinct innovation trends within the sector. ARKG homes in on genomics, gene editing, and molecular diagnostics—the tools and companies reshaping how disease is understood and treated at the DNA level. HLTH, launched much more recently, centers on artificial intelligence applications across the broader healthcare ecosystem, from drug discovery to medical imaging to healthcare IT platforms. The key distinction is their underlying exposure: genomic science versus AI-powered healthcare solutions.
How they differ
ARKG is the established genomics-and-CRISPR play, while HLTH is a nascent AI-in-healthcare fund. ARKG has been running since 10/31/2014 with $2.00B in assets under management, whereas HLTH arrived on 07/21/2026 with only $7.66M in assets. Both charge 0.75%, but ARKG's longer track record and vastly larger asset base mean tighter spreads and deeper liquidity. ARKG carries a beta of 2.37, suggesting meaningful market sensitivity; HLTH does not publish a beta figure. Neither fund distributes income—both are total-return vehicles focused on capital appreciation, so they will generate tax consequences primarily through sales gains.
Who each is best for
ARKG: Fits investors with a multi-year time horizon who believe genomic medicine, CRISPR applications, and precision diagnostics will drive long-term healthcare innovation. Works well for those comfortable with a concentrated bet on a specific innovation theme and willing to tolerate significant volatility.
HLTH: Designed for investors exploring the emerging intersection of AI and healthcare delivery, willing to accept the illiquidity and uncertainty of a very young, small fund, and confident that AI will reshape drug discovery, diagnostics, and hospital operations. Suits exploratory allocations rather than core holdings.
Key risks to know
- Single-theme concentration risk. Both funds are narrowly focused on discrete innovation stories—genomics for ARKG, AI for HLTH. If either theme underperforms or faces regulatory headwinds (gene editing restrictions, for instance), the fund lacks diversification to absorb the blow.
- Market sensitivity in ARKG. A beta of 2.37 means ARKG amplifies broader market movements. During equity selloffs, this fund is likely to fall harder than the broader market, which matters for investors managing downside risk.
- Severe liquidity disparity. HLTH's $7.66M in assets creates a liquidity bottleneck—wide bid-ask spreads, low trading volume, and potential difficulty exiting meaningful positions without moving the price. ARKG's $2.00B is substantially more liquid, but still smaller than large-cap healthcare alternatives.
- Early-stage fund uncertainty for HLTH. Launched on 07/21/2026, HLTH has almost no performance history. Its active management team's ability to pick winning AI-healthcare companies remains unproven, and the fund may face asset outflows if initial results disappoint.
- Valuations in growth and innovation funds. Both funds own companies betting on future breakthroughs, not today's earnings. Rising rates, tightening credit conditions, or slower adoption of genomic or AI-enabled solutions could crimp these companies' multiples sharply.
Bottom line
If you're drawn to the genomics and gene-therapy wave with a proven fund vehicle and acceptable liquidity, ARKG offers a nearly decade-old track record and meaningful assets. If you're betting on AI's near-term disruption of healthcare discovery and delivery and willing to accept a fund in its infancy with minimal trading liquidity, HLTH captures that thesis—but with no performance history to evaluate. Past performance is not indicative of future results.
AI-generated analysis for educational purposes only. Verify important details independently; past performance does not guarantee future results.
